We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BIRG:EURONEXT DUBLINBank of Ireland Group PLC Analysis

Data as of 2026-05-29 - not real-time

€17.44

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

The stock is trading above its short‑term and medium‑term moving averages, confirming a bullish technical backdrop. Momentum indicators such as the MACD are in bullish alignment and the RSI sits comfortably in the upper‑mid range, suggesting continued upward pressure. Volume has been trending higher, adding conviction to the price action. The price remains above a well‑defined support level while still leaving room below the nearby resistance zone.
Valuation metrics show the forward price‑to‑earnings multiple considerably below the sector average, implying a discount to peers. The dividend yield exceeds five percent and the payout ratio is under fifty percent, indicating a sustainable income stream. Recent earnings releases highlighted double‑digit loan growth, especially in the Irish franchise, and reaffirmed net interest income guidance for the year. Capital ratios are solid with a CET1 comfortably above fifteen percent and a net‑cash position that dwarfs total debt. However, operating cash flow turned negative and revenue growth is modestly down, tempering the optimism. The beta below one points to lower market volatility, while the thirty‑day price swing remains elevated, reflecting sector‑specific dynamics. Analyst consensus leans toward a buy recommendation with a target price notably above the current level. In this context, the stock presents an attractive blend of value pricing, dividend yield, and growth catalysts, making it a compelling candidate for investors with a medium‑to‑long horizon.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • bullish technical indicators
  • price near resistance level
  • high dividend yield

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • undervalued relative to peers
  • strong loan growth momentum
  • sustainable dividend payout

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • robust capital ratios and net‑cash position
  • low beta indicating reduced volatility
  • consistent dividend income

Key Metrics & Analysis

Financial Health

Revenue Growth-3.20%
Profit Margin30.37%
P/E Ratio15.2
ROE9.26%
ROA0.73%
P/B Ratio1.3
Op. Cash Flow€-783000000
Industry P/E16.6

Technical Analysis

TrendBullish
RSI59.2
Support€16.20
Resistance€17.80
MA 20€16.98
MA 50€16.43
MA 200€15.48
MACDBullish
VolumeIncreasing
Fear & Greed Index94.07

Valuation

Target Price€19.15
Upside/Downside9.84%
GradeUndervalued
TypeValue
Dividend Yield5.20%

Risk Assessment

Beta0.49
Volatility27.66%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.